β-Trace protein and prognosis in patients with atrial fibrillation receiving anticoagulation treatment

Chest

Volumn 144, Issue 5, 2013, Pages 1564-1570

  Vílchez, Juan Antonio ^a,b   Roldán, Vanessa ^c   Manzano Fernández, Sergio ^a   Fernández, Hermógenes ^c   Avilés Plaza, Francisco ^b   Martínez Hernández, Pedro ^b   Vicente, Vicente ^c   Valdés, Mariano ^a   Marín, Francisco ^a   Lip, Gregory Y H ^d  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA TRACE PROTEIN; BIOLOGICAL MARKER; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AGED; ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATED NEPHELOMETER; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHAD2 DS2 VASC SCORE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DISEASE ASSOCIATION; EMBOLISM; EVALUATION AND FOLLOW UP; FEMALE; GLOMERULUS FILTRATION RATE; HAS BLED SCORE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LASER NEPHELOMETER; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM;

EID: 84887457210     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0922     Document Type: Article

References (38)

1. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369- 2429.
2. Soliman EZ, Prineas RJ, Go AS, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010;159(6):1102- 1107.
3. Sarnak MJ, Levey AS, Schoolwerth AC, et al; American Heart Association Councils on Kidney in Cardiovascular Dis ease High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42(5):1050-1065.
4. Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599-607.
5. Hoffmann A, Conradt HS, Gross G, Nimtz M, Lottspeich F, Wurster U. Purification and chemical characterization of beta-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J Neurochem. 1993;61(2):451-456.
6. Urade Y, Fujimoto N, Hayaishi O. Purification and characterization of rat brain prostaglandin D synthetase. J Biol Chem 1985;260(23):12410-12415.
7. Eguchi Y, Eguchi N, Oda H, et al. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci U S A. 1997;94(26):14689-14694.
8. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K. Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 1999;45(4):567-568.
9. Verhave JC, Gansevoort RT, Hillege HL, De Zeeuw D, Curhan GC, De Jong PE. Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol. 2004;15(5):1316- 1322.
10. Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, Von Eckardstein A; Mild and Moderate Kidney Disease (MMKD) Study Group. Serum creatinine, cystatin C, and betatrace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 2010;56(5):740-749.
11. Schuligoi R, Grill M, Heinemann A, Peskar BA, Amann R. Sequential induction of prostaglandin E and D synthases in inflammation. Biochem Biophys Res Commun. 2005;335(3):684-689.
12. Taba Y, Sasaguri T, Miyagi M, et al. Fluid shear stress induces lipocalin-type prostaglandin D (2) synthase expression in vascular endothelial cells. Circ Res. 2000;86(9):967-973.
13. Inoue T, Eguchi Y, Matsumoto T, et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis. 2008;201(2):385-391.
14. Miwa Y, Oda H, Shiina Y, et al. Association of serum lipocalintype prostaglandin D synthase levels with subclinical atherosclerosis in untreated asymptomatic subjects. Hypertens Res 2008;31(10):1931-1939.
15. Manzano-Fernández S, Januzzi JL Jr, Boronat-Garcia M, et al. b-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011;57(7):849-858.
16. Manzano-Fernández S, López-Cuenca A, Januzzi JL, et al. Usefulness of b-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes. Am J Cardiol. 2012;110(9):1240-1248.
17. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125(13):1605-1616.
18. Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006;37(9):2294-2300.
19. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38(4):1229-1237.
20. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand fac tor levels are an independent risk factor for adverse events includ ing mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011;57(25):2496-2504.
21. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
22. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-272.
23. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
24. Lip GY, Andreotti F, Fauchier L, et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011;106(6):997-1011.
25. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
26. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204.
27. Zweig MH. ROC plots display test accuracy, but are still limited by the study design. Clin Chem. 1993;39(6):1345-1346.
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172.
29. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-577.
30. Matsumoto T, Eguchi Y, Oda H, et al. Lipocalin-type prostaglandin D synthase is associated with coronary vasospasm and vasomotor reactivity in response to acetylcholine. Circ J 2011;75(4):897-904.
31. Orenes-Piñero E, Manzano-Fernández S, López-Cuenca A, Marín F, Valdés M, Januzzi JL. b-Trace protein: from GFR marker to cardiovascular risk predictor. Clin J Am Soc Nephrol 2013;8(5):873-881.
32. Heeringa J, Van Der Kuip DA, Hofman A, et al. Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study. Arch Intern Med. 2007;167(4):382-387.
33. Astor BC, Shafi T, Hoogeveen RC, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012;59(5):653-662.
34. Banerjee A, Fauchier L, Vourc'h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013;61(20):2079-2087.
35. Roldán V, Marín F, Manzano-Fernandez S, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109(5):956-960.
36. Roldán V, Marín F, Díaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500-1507.
37. Gallego P, Roldán V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(2):312-318.
38. Lip G Y H, Lane DA. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation-focus on the elderly. Circ J. 2013;77(6):1380-1388.